Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYRNASDAQ:CMPXNASDAQ:ELUTNASDAQ:HRTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRAtyr PHARMA$3.75-1.3%$3.24$1.42▼$4.66$333.77M0.79931,298 shs991,820 shsCMPXCompass Therapeutics$2.09-0.5%$1.91$0.77▼$4.08$289.01M1.4920,626 shs529,883 shsELUTElutia$1.72+1.2%$2.28$1.67▼$5.24$70.07M0.9750,241 shs7,935 shsHRTXHeron Therapeutics$1.85-1.1%$2.09$1.04▼$3.93$282.24M1.332.28 million shs780,850 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRAtyr PHARMA-1.32%+14.68%+6.53%-13.19%+374,999,900.00%CMPXCompass Therapeutics-0.48%-0.48%+0.97%-28.42%+33.97%ELUTElutia+1.18%0.00%-24.89%-46.58%-49.11%HRTXHeron Therapeutics-1.07%-6.09%-16.10%+6.94%-46.69%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATYRAtyr PHARMA2.6623 of 5 stars3.61.00.00.03.23.30.6CMPXCompass Therapeutics3.8824 of 5 stars4.63.00.00.03.05.00.0ELUTElutia3.0287 of 5 stars3.53.00.00.02.93.30.6HRTXHeron Therapeutics3.7002 of 5 stars3.50.00.04.23.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRAtyr PHARMA 3.14Buy$18.60396.00% UpsideCMPXCompass Therapeutics 3.11Buy$13.13527.99% UpsideELUTElutia 3.00Buy$8.00365.12% UpsideHRTXHeron Therapeutics 3.00Buy$5.50197.30% UpsideCurrent Analyst Ratings BreakdownLatest ELUT, HRTX, CMPX, and ATYR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025ATYRAtyr PHARMAHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.00 ➝ $35.005/9/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $10.005/9/2025ELUTElutiaLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.004/28/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/22/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/21/2025CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$24.00 ➝ $24.004/21/2025CMPXCompass TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/11/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/4/2025CMPXCompass TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $24.004/2/2025CMPXCompass TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.004/2/2025CMPXCompass TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $6.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRAtyr PHARMA$235K1,420.28N/AN/A$1.54 per share2.44CMPXCompass Therapeutics$850K340.01N/AN/A$1.17 per share1.79ELUTElutia$23.71M2.96N/AN/A($1.66) per share-1.04HRTXHeron Therapeutics$148.52M1.90N/AN/A($0.23) per share-8.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRAtyr PHARMA-$50.39M-$0.81N/AN/AN/AN/A-79.44%-59.16%8/12/2025 (Estimated)CMPXCompass Therapeutics-$42.49M-$0.41N/AN/AN/AN/A-32.37%-30.67%8/11/2025 (Estimated)ELUTElutia-$37.66M-$1.93N/AN/AN/A-218.72%N/A-142.61%7/28/2025 (Estimated)HRTXHeron Therapeutics-$110.56M-$0.06N/AN/AN/A-20.31%N/A-12.72%8/5/2025 (Estimated)Latest ELUT, HRTX, CMPX, and ATYR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CMPXCompass Therapeutics-$0.12-$0.12N/A-$0.12N/AN/A5/8/2025Q1 2025ELUTElutia-$0.20-$0.21-$0.01-$0.21$6.65 million$6.03 million5/7/2025Q1 2025ATYRAtyr PHARMA-$0.19-$0.17+$0.02-$0.17N/AN/A5/6/2025Q1 2025HRTXHeron Therapeutics-$0.01$0.01+$0.02$0.01$37.08 million$38.90 million3/13/2025Q4 2024ATYRAtyr PHARMA-$0.23-$0.18+$0.05-$0.18$0.02 millionN/A2/27/2025Q4 2024CMPXCompass Therapeutics-$0.10-$0.11-$0.01-$0.11N/AN/A2/27/2025Q4 2024HRTXHeron Therapeutics-$0.03$0.02+$0.05$0.02$37.37 million$40.78 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATYRAtyr PHARMAN/AN/AN/AN/AN/ACMPXCompass TherapeuticsN/AN/AN/AN/AN/AELUTElutiaN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRAtyr PHARMA0.025.415.41CMPXCompass TherapeuticsN/A31.8431.84ELUTElutiaN/A0.940.85HRTXHeron TherapeuticsN/A2.281.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRAtyr PHARMA61.72%CMPXCompass Therapeutics68.43%ELUTElutia74.03%HRTXHeron Therapeutics80.01%Insider OwnershipCompanyInsider OwnershipATYRAtyr PHARMA3.70%CMPXCompass Therapeutics29.80%ELUTElutia27.60%HRTXHeron Therapeutics5.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRAtyr PHARMA5389.00 million80.84 millionOptionableCMPXCompass Therapeutics20138.28 million98.38 millionNot OptionableELUTElutia18040.74 million20.46 millionNot OptionableHRTXHeron Therapeutics300152.56 million143.33 millionOptionableELUT, HRTX, CMPX, and ATYR HeadlinesRecent News About These CompaniesPoint72 Asset Management L.P. Purchases Shares of 3,075,809 Heron Therapeutics, Inc. (NASDAQ:HRTX)May 22 at 4:42 AM | marketbeat.comStonepine Capital Management LLC Invests $1.07 Million in Heron Therapeutics, Inc. (NASDAQ:HRTX)May 20, 2025 | marketbeat.comTang Capital Management LLC Boosts Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX)May 20, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 660,971 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX)May 19, 2025 | marketbeat.comRaymond James Financial Inc. Buys Shares of 135,722 Heron Therapeutics, Inc. (NASDAQ:HRTX)May 15, 2025 | marketbeat.comJ. Goldman & Co LP Acquires Shares of 270,100 Heron Therapeutics, Inc. (NASDAQ:HRTX)May 14, 2025 | marketbeat.com300,000 Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) Bought by Bridgeway Capital Management LLCMay 14, 2025 | marketbeat.comQ2 Earnings Estimate for HRTX Issued By Northland CapmkMay 10, 2025 | marketbeat.comClearline Capital LP Cuts Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX)May 10, 2025 | marketbeat.comResults: Heron Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its EstimatesMay 9, 2025 | finance.yahoo.comHeron Therapeutics (NASDAQ:HRTX) Releases Earnings Results, Beats Expectations By $0.03 EPSMay 8, 2025 | marketbeat.comHeron Therapeutics Target of Unusually High Options Trading (NASDAQ:HRTX)May 8, 2025 | marketbeat.comEarnings call transcript: Heron Therapeutics beats Q1 2025 expectations, stock surgesMay 7, 2025 | investing.comHeron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2025 Earnings Call TranscriptMay 7, 2025 | insidermonkey.comHeron Therapeutics Inc (HRTX) Q1 2025 Earnings Call Highlights: Record EBITDA and Significant ...May 7, 2025 | finance.yahoo.comHeron Therapeutics, Inc.: Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate UpdatesMay 6, 2025 | finanznachrichten.deHeron Therapeutics, Inc. (HRTX) Q1 2025 Earnings Call TranscriptMay 6, 2025 | seekingalpha.comCompared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key MetricsMay 6, 2025 | zacks.comHeron Therapeutics (HRTX) Q1 Earnings and Revenues Top EstimatesMay 6, 2025 | zacks.comHeron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate UpdatesMay 6, 2025 | prnewswire.comHeron Therapeutics Announces Settlement with Mylan Related to CINVANTI® and APONVIE® Patent LitigationsMay 6, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELUT, HRTX, CMPX, and ATYR Company DescriptionsAtyr PHARMA NASDAQ:ATYR$3.75 -0.05 (-1.32%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$3.82 +0.08 (+2.00%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Compass Therapeutics NASDAQ:CMPX$2.09 -0.01 (-0.48%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.18 +0.10 (+4.55%) As of 05/23/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Elutia NASDAQ:ELUT$1.72 +0.02 (+1.18%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.72 0.00 (-0.29%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Heron Therapeutics NASDAQ:HRTX$1.85 -0.02 (-1.07%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.83 -0.02 (-1.08%) As of 05/23/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
